| Biological Sciences | 2021-2025 | 272 | US 56 | 99.73 |
| Infectious Diseases | Lifetime | 139 | US 70 | 99.55 |
| Molecular Medicine | Lifetime | 23 | US 8 | 99.51 |
| Epidemiology | Lifetime | 696 | US 357 | 99.10 |
| Clinical Pharmacology | Lifetime | 352 | US 154 | 98.54 |
| Applied Microbiology and Biotechnology | Lifetime | 36 | US 18 | 97.56 |
| Endocrinology | Lifetime | 151 | US 66 | 97.62 |
| Clinical Biochemistry | Lifetime | 233 | US 108 | 95.89 |
| Molecular Medicine | 2021-2025 | 7 | US 2 | 99.45 |
| Clinical Pharmacology | 2021-2025 | 32 | US 13 | 98.54 |
| Epidemiology | 2021-2025 | 203 | US 68 | 98.54 |
| Infectious Diseases | 2021-2025 | 112 | US 42 | 98.24 |
| Applied Microbiology and Biotechnology | 2021-2025 | 21 | US 6 | 95.67 |
| Endocrinology | 2021-2025 | 30 | US 9 | 93.70 |
| Clinical Biochemistry | 2021-2025 | 49 | US 11 | 87.25 |
| Antibiotic Resistance in Bacteria | Lifetime | 37 | US 11 | 99.80 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 36 | US 19 | 99.73 |
| Antibiotic Use and Resistance | Lifetime | 26 | US 9 | 99.73 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 13 | US 4 | 99.37 |
| Antifungal resistance and susceptibility | Lifetime | 71 | US 35 | 99.56 |
| Fungal Infections and Studies | Lifetime | 64 | US 32 | 99.50 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 88 | US 39 | 99.43 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 139 | US 73 | 99.26 |
| Infections and bacterial resistance | Lifetime | 22 | US 6 | 99.07 |
| Pneumonia and Respiratory Infections | Lifetime | 262 | US 109 | 99.04 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 208 | US 36 | 98.97 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 199 | US 88 | 98.75 |
| Bacterial biofilms and quorum sensing | Lifetime | 410 | US 152 | 97.72 |
| Nail Diseases and Treatments | Lifetime | 346 | US 133 | 97.20 |
| Infectious Diseases and Mycology | Lifetime | 441 | US 173 | 94.79 |
| Vibrio bacteria research studies | Lifetime | 745 | US 274 | 95.33 |
| Urinary Tract Infections Management | Lifetime | 870 | US 402 | 95.32 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 9 | US 3 | 99.71 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 5 | US 1 | 99.60 |
| Antibiotic Use and Resistance | 2021-2025 | 11 | US 2 | 99.39 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 19 | US 5 | 98.86 |
| Fungal Infections and Studies | 2021-2025 | 16 | US 6 | 99.26 |
| Antifungal resistance and susceptibility | 2021-2025 | 26 | US 8 | 99.27 |
| Infections and bacterial resistance | 2021-2025 | 3 | US 2 | 97.23 |
| Pneumonia and Respiratory Infections | 2021-2025 | 76 | US 22 | 97.68 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 62 | US 19 | 96.56 |
| Urinary Tract Infections Management | 2021-2025 | 52 | US 27 | 96.11 |
| Nail Diseases and Treatments | 2021-2025 | 142 | US 33 | 91.98 |
| Infectious Diseases and Mycology | 2021-2025 | 192 | US 47 | 82.80 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 566 | US 142 | 83.69 |
| Plant Pathogenic Bacteria Studies | 2021-2025 | 647 | US 95 | 79.68 |
| Vibrio bacteria research studies | 2021-2025 | 691 | US 113 | 79.46 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 187 | US 16 | 71.21 |
